HARMONY BIOSCIENCES HOLDINGS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.32 USD | +1.35% |
|
-0.27% | -9.23% |
| Apr. 11 | Harmony Biosciences, Bioprojet Enter Licensing Deal for Sleep Disorder Therapy | MT |
| Apr. 03 | Harmony Biosciences Begins Phase 3 Trial of Pitolisant to Treat Prader-Willi Syndrome Symptoms | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,057 | 2,493 | 3,268 | 1,892 | 1,665 | - | - |
| Enterprise Value (EV) 1 | 2,022 | 2,449 | 3,214 | 1,759 | 1,299 | 1,019 | 735.1 |
| P/E ratio | -14.6 x | 73.5 x | 18.6 x | 15.2 x | 9.94 x | 7.21 x | 5.77 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 12.9 x | 8.16 x | 7.46 x | 3.25 x | 2.34 x | 1.98 x | 1.7 x |
| EV / Revenue | 12.7 x | 8.02 x | 7.34 x | 3.02 x | 1.83 x | 1.21 x | 0.75 x |
| EV / EBITDA | 74.2 x | 23 x | 22.4 x | 8.13 x | 4.95 x | 2.81 x | 1.81 x |
| EV / FCF | -677 x | 24.9 x | 22.3 x | 8.03 x | 6.41 x | 3.62 x | 2.21 x |
| FCF Yield | -0.15% | 4.01% | 4.49% | 12.5% | 15.6% | 27.6% | 45.3% |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 56,889 | 58,472 | 59,318 | 58,572 | 56,791 | - | - |
| Reference price 2 | 36.15 | 42.64 | 55.10 | 32.30 | 29.32 | 29.32 | 29.32 |
| Announcement Date | 3/25/21 | 2/28/22 | 2/21/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 159.7 | 305.4 | 437.9 | 582 | 710.8 | 839.9 | 980.8 |
| EBITDA 1 | 27.26 | 106.4 | 143.6 | 216.4 | 262.5 | 363.3 | 406.5 |
| EBIT 1 | 16.99 | 87.53 | 120.2 | 192 | 242.9 | 325.1 | 400.1 |
| Operating Margin | 10.63% | 28.66% | 27.45% | 32.99% | 34.17% | 38.71% | 40.79% |
| Earnings before Tax (EBT) 1 | -36.94 | 37.43 | 104.7 | 173.4 | 231.3 | 322.3 | 399.8 |
| Net income 1 | -63.85 | 34.6 | 181.5 | 128.9 | 180 | 247.4 | 303.2 |
| Net margin | -39.97% | 11.33% | 41.44% | 22.14% | 25.33% | 29.46% | 30.91% |
| EPS 2 | -2.480 | 0.5800 | 2.970 | 2.130 | 2.949 | 4.066 | 5.078 |
| Free Cash Flow 1 | -2.987 | 98.26 | 144.3 | 219.1 | 202.6 | 281.3 | 333 |
| FCF margin | -1.87% | 32.17% | 32.95% | 37.64% | 28.51% | 33.49% | 33.95% |
| FCF Conversion (EBITDA) | - | 92.38% | 100.5% | 101.24% | 77.2% | 77.43% | 81.92% |
| FCF Conversion (Net income) | - | 284.01% | 79.51% | 170.02% | 112.57% | 113.69% | 109.85% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 3/25/21 | 2/28/22 | 2/21/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 80.73 | 91.21 | 85.31 | 107 | 117.2 | 128.3 | 119.1 | 134.2 | 160.3 | 168.4 | 154.8 | 173.1 | 187.3 | 196.4 | 180 |
| EBITDA | - | - | - | - | - | - | - | 52.97 | - | - | - | - | - | - | - |
| EBIT 1 | 21.05 | 28.63 | 27.56 | 33.12 | 11.9 | 47.61 | 40.42 | 46.9 | 64.51 | 40.2 | 49.42 | 57.2 | 64.71 | 65.95 | 60.35 |
| Operating Margin | 26.08% | 31.39% | 32.3% | 30.94% | 10.15% | 37.11% | 33.93% | 34.95% | 40.25% | 23.87% | 31.93% | 33.04% | 34.55% | 33.58% | 33.52% |
| Earnings before Tax (EBT) 1 | -10.52 | 24.48 | 23.38 | 29.23 | 7.967 | 44.1 | 37.78 | 44.1 | 51.83 | 39.69 | 47.95 | 60.97 | 62.93 | 63.79 | 58.29 |
| Net income 1 | -9.62 | 22.71 | 21.48 | 23.53 | 87.79 | 48.51 | 29.48 | 34.3 | 38.47 | 26.61 | 35.72 | 45.05 | 46.33 | 47.07 | 44.34 |
| Net margin | -11.92% | 24.9% | 25.18% | 21.99% | 74.91% | 37.81% | 24.75% | 25.56% | 24% | 15.8% | 23.08% | 26.02% | 24.73% | 23.97% | 24.63% |
| EPS 2 | -0.1700 | 0.3800 | 0.3500 | 0.3900 | 1.440 | 0.7900 | 0.4800 | 0.5600 | 0.6300 | 0.4500 | 0.6171 | 0.7100 | 0.8143 | 0.8300 | 0.7050 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/9/21 | 2/28/22 | 5/3/22 | 8/2/22 | 11/1/22 | 2/21/23 | 5/2/23 | 8/1/23 | 10/31/23 | 2/22/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | 34.4 | 44.3 | 54.1 | 133 | 367 | 646 | 930 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -2.99 | 98.3 | 144 | 219 | 203 | 281 | 333 |
| ROE (net income / shareholders' equity) | - | - | - | 29.6% | 37.7% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share 2 | - | - | - | 3.630 | 3.640 | 4.560 | - |
| Capex 1 | 0 | 0.3 | 0.17 | 0.31 | 0.8 | 0.85 | 1.36 |
| Capex / Sales | 0% | 0.1% | 0.04% | 0.05% | 0.11% | 0.1% | 0.14% |
| Announcement Date | 3/25/21 | 2/28/22 | 2/21/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
29.32
USD
Average target price
41.5
USD
Spread / Average Target
+41.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.23% | 1.67B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- HRMY Stock
- Financials Harmony Biosciences Holdings, Inc.
